Key takeaways
- The White House withdrew the Heidi Overton FDA nomination on November 17, 2026, one day before the Senate health committee was due to vote on it.
- Overton needed every one of the 12 Republicans on the 12-11 committee, and Chairman Bill Cassidy had said he remained undecided on the day of the withdrawal.
- Reporting from CNN and NBC News points to concerns over her managerial experience, her handling of vaccine questions and friction inside the MAHA movement.
- Republicans are trying to confirm Trump's pending nominees before Democrats take over the Senate in January, which narrows the time available for a replacement FDA pick.
The White House dropped the Heidi Overton FDA nomination on Tuesday, November 17, 2026, after it became clear she lacked the Senate votes to be confirmed as commissioner of the Food and Drug Administration. The Senate health committee had been scheduled to vote on her nomination on Wednesday. The withdrawal leaves the FDA, the federal agency that regulates drugs, vaccines, medical devices and much of the food supply, without a confirmed leader as a new Congress approaches.
CBS News reported that a senior administration official and other people familiar with the decision confirmed the withdrawal. Axios was first to report it. The Associated Press reported that the White House acted amid growing indications she did not have the votes needed for confirmation.

Why did the White House pull the Heidi Overton FDA nomination?
The arithmetic of the Senate Health, Education, Labor and Pensions (HELP) Committee left little room. According to the AP, Overton would have needed the votes of all 12 Republicans on the panel, while Democrats hold 11 seats. The Hill noted that losing a single Republican would be enough to sink the nomination in committee if every Democrat opposed it.
The committee’s chairman had not committed. Republican Sen. Bill Cassidy of Louisiana, a physician who chairs the panel, said earlier on Tuesday that he remained undecided, according to NTD’s report of the AP story. Before her September confirmation hearing, Cassidy had written on X that he had “strong concerns” about her nomination, citing her lack of managerial experience.
A floor vote was not seen as a ready alternative. The Hill reported that GOP leaders could have tried to bring the nomination to the Senate floor without a committee vote, but that route would likely have faced significant obstacles. The AP said that without committee support she had little chance of winning a full Senate vote.
Who is Heidi Overton and what were the objections?
Overton is a physician and a White House domestic policy official. The Hill described her as deputy director of the White House Domestic Policy Council, closely involved in President Donald Trump’s health agenda. NBC News noted that before joining the White House she was chief policy officer at the conservative think tank America First Policy Institute. Trump named her as his nominee in August 2026.

Objections came from more than one direction. The AP reported that she faced bipartisan questions about her willingness to break from Trump, particularly over his unsupported claims about the dangers of childhood vaccines. The AP also said her selection had been viewed as a way to bring a stabilizing Trump loyalist to the agency after a tumultuous year under Dr. Marty Makary.
CNN reported a separate strand of friction. It said that as a senior White House adviser, Overton had acted as the main conduit between Health and Human Services leaders pursuing key MAHA policies and top White House officials who had stalled them, which created frustration and distrust within the broader MAHA movement. MAHA refers to the “Make America Healthy Again” agenda associated with the administration’s health policy.
What does the withdrawal mean for the FDA and the Senate calendar?
NBC News reported that the FDA has been without a permanent commissioner for some time. The Hill added that the agency has been roiled by an exodus of top staff and is viewed by many in the healthcare industry as less trustworthy and more politicized than under any previous administration. Some health industry analysts said the instability would likely have continued under Overton.

Time is a constraint. The AP reported that Republicans are racing to confirm all of Trump’s current nominees before handing power to Senate Democrats in January. The Hill has reported that Democrats won both the House and the Senate in the midterm elections. A new nominee would need to be named, scheduled for a hearing and cleared by the same committee, all within a short lame-duck period. The sources reviewed did not report a replacement candidate or a timetable.
The episode also lands as the administration faces a more assertive Congress. For related context on how the executive branch is managing its dealings with lawmakers, see Intelligence Report’s coverage of the Will Scharf memo on agency staff testimony.
How are the competing camps reading the decision?
The sources describe the withdrawal mainly as a failure to assemble Republican votes rather than a Democratic victory. The Hill framed it as the result of resistance from Senate Republicans over various policy issues. NBC News said the move followed concerns raised by Republicans. That framing matters because the committee’s one-vote margin gave individual Republican senators decisive leverage.
Supporters of the nomination had argued that Overton knew the administration’s health priorities and could steady an agency in turmoil. Critics, including some within the MAHA movement and some senators, questioned her independence, her management experience or her record on stalled policies. The White House has not, in the reporting reviewed, offered a detailed public explanation beyond confirming the withdrawal.
What to watch
- A new nominee: whether the White House names a replacement for FDA commissioner, and whether that person is an administration insider or an outside figure.
- The HELP Committee schedule: the Wednesday, November 18 vote is now moot. Any rescheduled hearing would signal how quickly Republicans hope to act before January.
- Cassidy’s statements: the committee chairman’s public criteria for a future nominee, particularly on vaccines and management experience.
- Other pending nominations: how many of Trump’s remaining nominees Senate Republicans can confirm before Democrats take control.
- Acting FDA leadership: any announcement on who runs the agency day to day while the post remains unfilled.
Frequently asked questions
Why was Heidi Overton's FDA nomination withdrawn?
The White House pulled it on November 17, 2026, amid growing indications she lacked the votes for Senate confirmation. According to the Associated Press, she needed all 12 Republicans on the 12-11 HELP Committee, and chairman Bill Cassidy had said he was still undecided on the day of the withdrawal.
Who is Heidi Overton?
Heidi Overton is a physician and White House domestic policy official whom President Trump named in August 2026 as his pick for FDA commissioner. The Hill describes her as deputy director of the Domestic Policy Council. She previously served as chief policy officer at the America First Policy Institute, according to NBC News.
Who will lead the FDA now?
The reporting reviewed does not name a replacement nominee or an acting leader. NBC News reported the FDA has been without a permanent commissioner. Any new nominee would need Senate health committee action, while Republicans race to confirm pending nominees before Democrats take control of the Senate in January.
Sources
- White House drops Heidi Overton's nomination for FDA commissioner | CBS News
- White House drops Trump's FDA pick ahead of confirmation vote | CNN
- White House withdraws Heidi Overton's FDA nomination after Republicans raise concerns | NBC News
- White House pulls nomination of Heidi Overton to lead the FDA | The Associated Press via NBC New York
- White House pulls U.S. FDA nominee Heidi Overton after wavering support from Senate Republicans | The Associated Press via CP24
- White House pulls nomination of Heidi Overton to lead FDA | The Hill
- White House Pulls FDA Nominee Heidi Overton | NTD
- White House deputy chief of staff departs under Miller shake-up | The Hill
- Heidi Overton | Wikipedia
Top image: TuendeBede / Pixabay
This article was produced by the Intelligence Report Desk. Sources are linked below.
